Hangzhou Moin Pharmaceutical Technology

Hangzhou Moin Pharmaceutical Technology is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on precision oncology and immunology, utilizing advanced drug discovery platforms such as structure-based drug design and fragment-based drug discovery. Its lead candidate, MN-008, is a highly selective, irreversible FGFR4 inhibitor currently being evaluated in Phase 1 clinical trials for the treatment of hepatocellular carcinoma. Moin Pharma aims to address significant unmet medical needs through the development of high-potency covalent inhibitors and other targeted modalities. The company's pipeline also includes promising programs targeting HPK1 and KRAS G12C, supported by prominent venture capital investors.